| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Fas | Human Fas / TNFRSF6 / CD95 Protein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $290.00 50ug | |||
| Fas | Human Fas / TNFRSF6 / CD95 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $295.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Xelafaslatide | ONL-1204 | Phase 2 Clinical | Onl Therapeutics | Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Kanglaite | Approved | Zhejiang Kanglaite Pharmaceutical Co Ltd | Kanglaite | Mainland China | Liver Neoplasms; Carcinoma, Non-Small-Cell Lung | Zhejiang Kanglaite Pharmaceutical Co Ltd | 1997-01-01 | Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
